• Explore /
  • Poster
  • / EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.

EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.

Abstract Poster

Authors

null

Jeffrey Howard Lipton

Princess Margaret Hospital, Toronto, ON, Canada

Jeffrey Howard Lipton , Charles Chuah , Agnes Guerci-Bresler , Gianantonio Rosti , David Simpson , Stephanie Lustgarten , Nikolaus S. Trede , Victor M. Rivera , Tim Clackson , Frank G. Haluska , Michele Baccarani , Jorge E. Cortes , Francois Guilhot , Andreas Hochhaus , Timothy P. Hughes , Hagop M. Kantarjian , Neil P. Shah , Moshe Talpaz , Michael W.N. Deininger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01650805

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7023)

DOI

10.1200/jco.2014.32.15_suppl.7023

Abstract #

7023

Poster Bd #

15

Abstract Disclosures

Similar Posters

First Author: Jeffrey H. Lipton

First Author: Elias Jabbour

Poster

2016 ASCO Annual Meeting

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

First Author: Jorge E. Cortes

First Author: Hagop M. Kantarjian